| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
A new study suggests a potential link between the use of psychedelics like magic mushrooms and LSD and improved sexual function up to six months after they have been consumed.
Believed to be the first scientific research into the effects of psychedelics and sex, the new findings combine responses from nearly 300 participants who reported overall improvements after a psychedelic experience. Keep reading.
The Food and Drug Administration (FDA) has recently accepted a New Drug Application (NDA) from Lykos Therapeutics for the use of MDMA-assisted therapy in treating Post-Traumatic Stress Disorder (PTSD).
This decision marks a significant milestone in the journey toward potentially integrating psychedelic-assisted therapies into mainstream medical practice. Lykos has been at the forefront of research on this innovative treatment approach. Keep reading.
Psilocybin, the psychedelic substance in “magic mushrooms,” has been featured in the media as researchers study its potential clinical applications. Two states have undertaken regulated programs for its effective use and several cities have passed decriminalization measures for a variety of natural psychedelics including these mushrooms.
Yet at the federal level, psilocybin is still illegal. Researchers analyzed data on law enforcement seizures of psychedelic mushrooms to better understand their use prevalence. Keep reading.
A majority of Canadians (79.3% ) consider psilocybin-assisted therapy to be “a reasonable medical choice” for addressing “existential distress” during the final stages of life, a team of 12 experts behind the new research revealed.
A study, published last month in the journal Palliative Care, is based on data collected from an online survey that was conducted in Canada between November 23 and December 4, 2022. Find out more.
In related news, Washington Doctor Sunil Aggarwal is suing the DEA to allow him to lawfully use psilocybin therapy with terminally ill patients. Here's the latest claim.
See Also: Last Week's Edition Of ‘Psyched'
AdvisorShares Psychedelics ETF (NYSE:PSIL) opened Monday, Feb. 12 at $1.44, following prior weeks’ openings at $1.42, $1.38 and $1.37 (Feb. 5, Jan. 29 and Jan. 22, respectively.)
On Friday, Feb. 9 it closed at $1.44, following prior weekly closes at $1.43, $1.43 and $1.37 (Feb. 2, Jan. 26 and Jan. 19, respectively.)
Last week’s highest was $1.47, vs. prior weekly highest at $1.60, $1.44 and $1.45.
Week’s lowest was $1.37, vs. prior weekly lowests at $1.39, $1.38 and $1.34.
Stock trading numbers above according to Benzinga Pro, our all-the-information-you-need streaming platform helping you invest smarter – Come join us and see for yourself!
Also, Benzinga Cannabis Conferences are coming to Los Angeles!
Join the Benzinga Cannabis Market Spotlight: California, and unlock the future of cannabis at the premier networking event in Culver City on February 22. Connect with top industry leaders, gain insider insights into the investment landscape and shape the evolving markets in California and beyond. Don’t miss this chance to be at the forefront of the cannabis industry’s growth and innovation!
Join now.
Posted In: ATAI CMND CMPS DRUG ENVB GHRS IXHL MNMD NUMIF PSIL SEEL SILO
